Form 4: ATAI Life Sciences N.V.: Chief Scientific Officer Granted Stock Options

Glenn Frank Short, Chief Scientific Officer of ATAI Life Sciences N.V., was granted stock options for 757,915 common shares on March 3, 2025.

Summary

• Glenn Frank Short, the Chief Scientific Officer of ATAI Life Sciences N.V., was granted stock options.
• The transaction occurred on March 3, 2025.
• The stock options are for 757,915 common shares.
• The exercise price of the stock options is $1.50.
• The options vest as to 25% on January 1, 2026, and the remaining shares vest in 36 equal monthly installments thereafter.
• The options expire on March 3, 2035.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The granting of stock options is a standard practice and generally viewed favorably as it aligns management's interests with shareholders.

Positives

• The grant of stock options to the Chief Scientific Officer aligns his interests with those of the shareholders.
• The vesting schedule incentivizes long-term commitment and performance.

Industry Context

Stock option grants are a common practice in the biotech industry to incentivize key executives and align their interests with the long-term success of the company.

Comparison to Industry Standards

• Stock option grants are a standard form of compensation for executives in the biotechnology industry.
• The vesting schedule of 25% on the first vesting date followed by monthly installments is a typical structure.
• Comparable companies in the biotech sector, such as Compass Pathways and MindMed, also utilize stock options as part of their executive compensation packages.

Stakeholder Impact

• Shareholders may view the stock option grant positively as it incentivizes the Chief Scientific Officer to drive long-term value.
• Employees may see this as a positive sign of investment in key personnel.

Key Dates